BioNexus Gene Lab Corp. (BGLC) 2025 Annual Report: Key Highlights & Investor Insights

Executive Summary

BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The report contains several developments and risk disclosures that could materially impact shareholder value and are important for investor consideration.

Key Points & Developments

• Corporate Structure & Operations:
  • BGLC operates through two wholly owned Malaysian subsidiaries: Chemrex Corporation Sdn. Bhd. (“Chemrex”) and MRNA Scientific Sdn. Bhd. (“MRNA Scientific”).
  • Chemrex focuses on wholesale sales of chemical raw materials, primarily fibre-reinforced polymers (FRP), servicing industrial, medical, appliance, aero, automotive, mechanical, and electronics manufacturers across Southeast Asia including Malaysia, Indonesia, and Vietnam.
  • MRNA Scientific offers blood-based genomic screening services, targeting risk analysis for selected diseases such as certain cancers, inflammatory conditions, and osteoarthritis. The company’s proprietary algorithm and biomarker technology, developed by Dr. Liew, is a key asset.
• IPO, Public Float, and Capital Raising Events:
  • BGLC completed an IPO in July 2023, issuing 1,437,500 shares (including over-allotments) at \$4.00 per share, raising gross proceeds of \$5.75 million. Subsequently, the company established an At-the-Market (ATM) equity program, with 53,478 shares sold for proceeds of \$267,311 as of the 10-K filing.
  • As of June 30, 2025, public float was reported at \$4,814,884.
• Nasdaq Listing Challenges & Annual Meeting Irregularities:
  • BGLC received notice from Nasdaq in November 2023 for non-compliance with Rule 5550(a)(2) (minimum \$1.00 bid price). The company was granted until May 6, 2024, to regain compliance, but shareholder approval for a reverse stock split was compromised due to alleged unlawful proxy solicitation by former officers.
  • The reverse stock split was crucial for maintaining Nasdaq listing. Failure to implement it due to dissident shareholder actions puts the listing at risk and constitutes a material event for investors.
• Audit Committee Actions & Governance:
  • Internal audit programs have been authorized to address governance lapses at Chemrex, with corrective actions underway. Related party transactions flagged and reviewed; all accounting treatments disclosed.
• Financial Position and Risks:
  • BGLC is classified as a “non-accelerated filer”, “smaller reporting company”, and “emerging growth company”. It has not achieved profitable operations over the past three years, and net losses are expected to continue as substantial resources are devoted to commercialization and R&D.
  • Additional capital is likely required to fund ongoing operations, marketing expansion (notably for the VitaGuard™ platform), and potential acquisitions. Dilution risks and potential restrictive debt covenants are highlighted.
  • Cash and cash equivalents as of December 31, 2025: \$2,486,383. Fluctuations in foreign currency (Malaysian Ringgit vs. USD) are a material risk.
• Business Risks & Industry Factors:
  • Both Chemrex and MRNA Scientific operate in cyclical and competitive industries. Chemrex’s business is sensitive to economic downturns, especially in construction, energy, appliance, and medical devices.
  • MRNA Scientific’s proprietary genomic screening biomarkers have not undergone clinical trials; regulatory approval, market acceptance, and protection of intellectual property remain critical risks.
  • Product liability exposure is significant due to the nature of diagnostic services; MRNA Scientific does not currently have insurance against such claims.
  • Expansion plans outside Malaysia expose the company to cross-border operational, regulatory, and currency risks.
• Human Capital and Incentive Plans:
  • Employment agreements are in place for officers. The 2025 Equity Incentive Plan was approved, allocating approximately 403,000 shares for issuance.
  • The company is seeking to expand its executive team and business development resources.
• Regulatory and Compliance Risks:
  • As a smaller reporting company, BGLC is exempt from some Sarbanes-Oxley Act requirements and executive compensation disclosures. However, this may result in decreased transparency and could affect investor confidence.

Price Sensitive and Material Information for Shareholders

• Nasdaq Listing at Risk:
  • Failure to execute a reverse stock split due to shareholder dissident actions jeopardizes the company’s Nasdaq listing. Loss of the listing could severely impact market liquidity and share value.
• Continued Operating Losses:
  • The company has not achieved profitability for three years and expects losses to continue. This increases the risk of dilution and financing difficulties.
• Potential Dilution and Capital Constraints:
  • Additional capital raising (equity or debt) is anticipated. Shareholders may face dilution, and unfavorable financing terms could affect their holdings.
• Annual Meeting Irregularities:
  • Alleged unlawful proxy solicitation and governance lapses may affect future voting outcomes and corporate stability.
• Regulatory and Product Risks:
  • Lack of clinical trials for MRNA Scientific’s biomarkers, potential product liability claims, and insurance gaps could materially impact the company’s financials.
• Currency Risk:
  • Significant exposure to fluctuations in Malaysian Ringgit vs. USD may affect reported revenues and asset values.

Investor Takeaways

• BGLC’s share price may be influenced by its ability to maintain Nasdaq listing, raise capital, achieve profitability, and successfully commercialize its genomic screening business.
• Corporate governance issues, including annual meeting irregularities and internal audit findings, may affect investor confidence and share value.
• Risks related to regulatory approvals, market acceptance, and cross-border expansion present substantial uncertainty.
• Investors should monitor developments related to the reverse stock split, capital raising activities, and ongoing Nasdaq compliance.

Disclaimer

The information contained in this article is based on the company’s Annual Report on Form 10-K for the year ended December 31, 2025. This article does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The company’s operations, financial position, and share value are subject to risks and uncertainties as described herein.

View BioNexus Gene Lab Corp Historical chart here